Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Language
Publication year range
1.
Front Surg ; 10: 1120930, 2023.
Article in English | MEDLINE | ID: mdl-37139191

ABSTRACT

Objective: To investigate the ability of preoperative neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) to predict postoperative nausea and vomiting (PONV) after total knee arthroplasty (TKA). Methods: The clinical data of 108 male patients with hemophilia A who underwent TKA an our institution were collected and analyzed. Confounding factors were adjusted by propensity score matching. The best cutoffs of the NLR and PLR were determined by the area under the receiver operating characteristic curve (ROC). The predictive ability of these indexes was assessed by measuring the sensitivity, specificity, and positive and negative likelihood ratios. Results: There were significant differences in the use of antiemetics (p = 0.036) and the incidence of nausea (p < 0.001) and vomiting (p = 0.006) between the two groups (NLR <2 and ≥2). An increase in preoperative NLR was an independent risk factor for PONV in patients with hemophilia A (p < 0.05). ROC analysis showed that NLR significantly predicted the occurrence of PONV (cutoff value: 2.20, ROC: 0.711, p < 0.001). In turn, the PLR did not strongly predict PONV. Conclusions: The NLR is an independent risk factor for PONV in patients with hemophilia A and can significantly predict this event. Thus, follow-up monitoring is essential for these patients.

2.
Arch. endocrinol. metab. (Online) ; 63(3): 222-227, May-June 2019. tab, graf
Article in English | LILACS | ID: biblio-1011165

ABSTRACT

ABSTRACT Objective Type 2 diabetes (T2DM) is characterized by the progressive deterioration of pancreatic islet β-cell function over time and insulin resistance. Knowing more about the differences in pancreatic islet function in T2DM patients who have had diabetes for different lengths of time can help improve therapy for T2DM. Subjects and methods We conducted a cross-sectional study to compare islet β-cell function and insulin resistance in T2DM patients (n = 3,254) who had had diabetes for different lengths of time and those in normal controls (n = 794) using ANOVA and LSD analysis. Results We found that compared with that in normal controls, HOMA-β in T2DM patients with a history of diabetes of less than 1 year was lower (approximately 52% of that of normal controls, p = 0.003), while HOMA-IR in these patients was higher (approximately 50% of that of normal controls, p = 0.007). Compared with that in other diabetic patients, HOMA-β in patients with a history of diabetes of more than 30 years was the lowest. HOMA-IR in patients with a history of diabetes of between 20 and 30 years was lower than that in other diabetic patients (p < 0.05). Conclusions There were obvious decreases in HOMA-β and increases in HOMA-IR in T2DM patients with a history of diabetes of less than 1 year compared with those in normal controls. Therefore, early screening and intervention for T2DM might help improve islet function and delay the progression of diabetes.


Subject(s)
Humans , Adult , Middle Aged , Aged , Insulin Resistance , Diabetes Mellitus, Type 2/metabolism , Insulin-Secreting Cells/metabolism , Homeostasis/physiology , Time Factors , Blood Glucose/analysis , Body Mass Index , Case-Control Studies , Cross-Sectional Studies , Islets of Langerhans/metabolism , Diabetes Mellitus, Type 2/physiopathology , Glucose Tolerance Test , Models, Biological
3.
Arch Endocrinol Metab ; 63(3): 222-227, 2019.
Article in English | MEDLINE | ID: mdl-31066759

ABSTRACT

OBJECTIVE: Type 2 diabetes (T2DM) is characterized by the progressive deterioration of pancreatic islet ß-cell function over time and insulin resistance. Knowing more about the differences in pancreatic islet function in T2DM patients who have had diabetes for different lengths of time can help improve therapy for T2DM. SUBJECTS AND METHODS: We conducted a cross-sectional study to compare islet ß-cell function and insulin resistance in T2DM patients (n = 3,254) who had had diabetes for different lengths of time and those in normal controls (n = 794) using ANOVA and LSD analysis. RESULTS: We found that compared with that in normal controls, HOMA-ß in T2DM patients with a history of diabetes of less than 1 year was lower (approximately 52% of that of normal controls, p = 0.003), while HOMA-IR in these patients was higher (approximately 50% of that of normal controls, p = 0.007). Compared with that in other diabetic patients, HOMA-ß in patients with a history of diabetes of more than 30 years was the lowest. HOMA-IR in patients with a history of diabetes of between 20 and 30 years was lower than that in other diabetic patients (p < 0.05). CONCLUSIONS: There were obvious decreases in HOMA-ß and increases in HOMA-IR in T2DM patients with a history of diabetes of less than 1 year compared with those in normal controls. Therefore, early screening and intervention for T2DM might help improve islet function and delay the progression of diabetes.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Homeostasis/physiology , Insulin Resistance , Insulin-Secreting Cells/metabolism , Adult , Aged , Blood Glucose/analysis , Body Mass Index , Case-Control Studies , Cross-Sectional Studies , Diabetes Mellitus, Type 2/physiopathology , Glucose Tolerance Test , Humans , Islets of Langerhans/metabolism , Middle Aged , Models, Biological , Time Factors
4.
Medicine (Baltimore) ; 96(44): e8490, 2017 Nov.
Article in English | MEDLINE | ID: mdl-29095309

ABSTRACT

Lymphatic vessel invasion (LVI) is promising in determining prognosis and treatment strategies, but the application of LVI as a histopathological criterion in breast cancer patients especially those of different subgroups is controversial. This research aims to evaluate the prognostic value of LVI assessed by D2-40 not only in patients with early invasive breast cancer but also in lymph node-negative, lymph node-positive, luminal A-like, luminal B-like, HER2-enriched, and triple-negative subgroups.The study cohort included 255 patients with a median follow-up of 101 months. Immunohistochemical staining for D2-40 was performed to identify LVI.LVI was present in 64 (25.1%), 15 (12.1%), 49 (37.4%), 19 (20.9%), 23 (27.7%), 13 (31.7%), and 9 (22.5%), respectively, in the whole cohort, lymph node-negative, lymph node-positive, luminal A-like, luminal B-like, HER2-enriched, and triple-negative patients. LVI was associated with large tumor size (P = .04), high histological grade (P = .004), involved lymph node (P < .001), and high expression of Ki-67 (P = .003). No significant difference was found among patients with different subtypes and LVI status. The presence of LVI was significantly associated with adverse disease-free survival in the whole cohort (P < .001), lymph node-negative (P < .001), lymph node-positive (P < .001), luminal A-like (P < .001), and luminal B-like patients (P < .001) in both of the univariate and multivariate survival analysis.This study indicated that the presence of LVI stained by D2-40 provided independent prognostic information not only in the whole cohort but also in the subgroup of patients with lymph node-negative, lymph node-positive, luminal A-like, and luminal B-like diseases, which may make a case for routine clinical assessment of LVI using D2-40.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/analysis , Breast Neoplasms/immunology , Breast Neoplasms/pathology , Lymphatic Vessels/pathology , Adult , Aged , Biomarkers, Tumor , China , Disease-Free Survival , Female , Follow-Up Studies , Humans , Immunohistochemistry , Lymphatic Metastasis , Lymphatic Vessels/immunology , Middle Aged , Neoplasm Invasiveness/immunology , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL
...